Abstract
Telomerase reverse transcriptase (TERT) promoter mutations have been found to increase telomerase activity and thereby drive oncogenic processes. TERT mutations have been identified in many types of malignancies and are frequently found in anaplastic, follicular, and papillary thyroid cancer. Genetic testing has become an important tool in evaluating thyroid lesions especially with indeterminant fine needle biopsy results. Studies have shown TERT promoter mutations to be associated with poor prognosis and are only very rarely found in benign thyroid lesions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
